Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 72

Results For "IT"

10142 News Found

Merck opens €150 million manufacturing facility in Ireland
News | September 19, 2025

Merck opens €150 million manufacturing facility in Ireland

Merck opens first climate-neutral manufacturing facility in Ireland


FDA completes inspection of Indoco’s API manufacturing facility at Patalganga with zero observations
Drug Approval | September 19, 2025

FDA completes inspection of Indoco’s API manufacturing facility at Patalganga with zero observations

The inspection concluded with zero form 483 observations


Bayer inaugurates new phytomedicines lab facility
News | September 18, 2025

Bayer inaugurates new phytomedicines lab facility

The lab will facilitate the development of herbal and natural-based solutions


Lilly to build $5 billion manufacturing facility in Virginia
News | September 17, 2025

Lilly to build $5 billion manufacturing facility in Virginia

This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year


KIMS Hospital Bengaluru commences operations of new hospital in Bengaluru
Hospitals | September 17, 2025

KIMS Hospital Bengaluru commences operations of new hospital in Bengaluru

The state-of-the-art facility is a 450-bedded, multi-specialty tertiary care hospital,


Zen Multispeciality Hospital bags CII WR Health Innovation award 2025
News | September 16, 2025

Zen Multispeciality Hospital bags CII WR Health Innovation award 2025

The hospital was recognised as a Winner (Medium) in the category of Best Academic Institution (Government/Private)


Rona submits IND for GalNAc-conjugated siRNA targeting obesity
Drug Approval | September 16, 2025

Rona submits IND for GalNAc-conjugated siRNA targeting obesity

RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options


Ascletis' ASC30 obesity drug shows 75-day half-life in US Study
Clinical Trials | September 16, 2025

Ascletis' ASC30 obesity drug shows 75-day half-life in US Study

Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity